The table below shows Moderna, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
-$1.87B
-$3.00B
-$3.12B
$4.98B
$13.62B
$2.03B
Capital expenditure
$192.00M
$1.05B
$707.00M
$400.00M
$284.00M
$68.00M
Investing cash flow
$1.95B
$1.95B
$4.21B
-$5.18B
-$8.52B
-$1.67B
Dividends paid
-
-
-
-
-
-
MRNA operating cash flow (10-K history)
Moderna, Inc. reported operating cash flow of -$1.87B for fiscal year 2025. That is up 37.6% from -$3.00B in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from $66.73M (FY 2016) to -$1.87B. Figures come from the company's audited annual reports as filed with the SEC.
